Controlled trial demonstrates that indinavir plus two nucleoside analogues slows HIV-1 progression in individuals with low CD4 counts, indicating a potential treatment benefit.
Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine.
No takes yet. Share an insight, caveat, or question.
Hammer et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: